<DOC>
	<DOC>NCT00566397</DOC>
	<brief_summary>The purpose of this study is to evaluate the efficacy and safety of PF 04494700 in participants with mild to moderate Alzheimer's disease.</brief_summary>
	<brief_title>A Phase 2 Study Evaluating The Efficacy And Safety Of PF 04494700 In Mild To Moderate Alzheimer's Disease</brief_title>
	<detailed_description />
	<mesh_term>Alzheimer Disease</mesh_term>
	<criteria>Mini Mental State Exam (MMSE) score between 1426 (inclusive) at screening. Participants must be receiving acetylcholinesterase inhibitors on a stable dose for at least 4 months prior to randomization Current evidence or history of neurological, psychiatric and any other illness that could contribute to nonAlzheimer's dementia. Known history of familial AD or any evidence for early onset AD known or possibly associated with genetic mutations. Evidence or history of diabetes mellitus Type 1 or Type 2. History or symptoms of autoimmune disorders.</criteria>
	<gender>All</gender>
	<minimum_age>50 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2013</verification_date>
	<keyword>RI RI Study Rage Inhibitors</keyword>
</DOC>